ACLX

Arcellx, Inc. Common Stock

$115.07 +0.03%

Recent alerts on ACLX

All signals →

News This $64 Million Biotech Exit Seemingly Missed a 77% One-Day Surge on Gilead Takeover Deal

News Gilead Ups 2025 Outlook, Eyes Lenacapavir Launch For HIV Prevention

News Expert Ratings For Arcellx

SEC filing ACLX Completes $115.00/Share Tender Offer, $5.00 CVR, $5.5B Deal, 77.2% Acceptance, All Conditions Met, Merger Effective 4/28/26

News Gilead extends Arcellx tender offer again

News Gilead Acquisition Spree Continues With $3 Billion Tubulis Deal

News Gilead to acquire Tubulis GmbH for $5B

Insider trade Sale by Elghandour Rami (President, CEO and Chairman of the Board)

Insider trade Sale by Michelle Gilson (CHIEF FINANCIAL OFFICER)

News Accenture Buys Verum Partners To Supercharge Latin America Mega-Projects With AI

News Gilead Snaps Up Arcellx For $115 Per Share — A $7.8 Billion Bet On Cancer Therapy

Scanner Unusual buy pressure (9.1x avg, 34% up-volume, +0.1% / +0.10 intraday, above VWAP)

News Arcellx Surges as Gilead’s $7.8B Offer Locks In a 68% Premium

News Gilead Buys Arcellx To Fast-Track Next-Gen Myeloma Drug

News US Premarket Movers: Arcellx, Domino’s, MoonLake, Vanda, Veris

News Gilead Sciences to buy Arcellx in deal worth up to $7.8B

News M&A Snapshot: Gilead acquires Arcellx for $7.8B

News Gilead to Buy Biotech Arcellx in Deal Worth Up to $7.8 Billion

Insider trade Sale by Christopher Heery

Insider trade Sale by Christopher Heery

News Legend Biotech Arcellx rise after FDA draft guidance on multiple myeloma trials

Get push alerts for ACLX

Add it to your watchlist in the app and receive every signal the moment it fires.

Download for iOS

Download for iOS